People with hereditary angioedema (HAE) typically experience a markedly delayed diagnosis — from three to 26 years following the onset of symptoms — that results in a greater disease burden for patients, with growing HAE-related expenses from hospitalizations, medications, potentially unnecessary surgeries, and a plethora of doctor visits, according…
Transitioning from other prophylactic, or preventive, treatments, to Orladeyo (berotralstat) or Takhzyro (lanadelumab) can take some time and adjustment, but helps to safely prevent swelling episodes in hereditary angioedema (HAE) patients. That’s according to a study reporting the process of such a treatment transition for four family members…
Changes in the levels of certain metabolites — molecules that take part in metabolism — in the blood may serve as accurate biomarkers to diagnose hereditary angioedema (HAE), a study suggests. Moreover, ratios of metabolite levels also were able to differentiate between people with HAE and those with…
Children in Egypt with hereditary angioedema (HAE) wait an average of three years to be diagnosed, according to a small study. Delayed diagnosis was common despite more than half the children in the study having a family history of the disease. About half of the 18 patients in the study…
The oral medication Orladeyo (berotralstat) is now approved in Peru as a prophylactic, or preventive, treatment to reduce the risk of swelling attacks in people with hereditary angioedema (HAE), ages 12 and older. The approval from Peru’s General Directorate of Medicines, Supplies and Drugs comes just months after…
KalVista Pharmaceuticals has started a clinical trial to test the oral medication sebetralstat as an on-demand treatment for swelling attacks in children with hereditary angioedema (HAE), ages 2-11. The launch of KONFIDENT-KID (NCT06467084) came just a few weeks after KalVista asked the U.S. Food and…
Switching to Orladeyo (berotralstat) may help reduce the frequency and duration of swelling attacks in people with hereditary angioedema (HAE) who have normal levels and activity of a protein called C1-inhibitor, according to a European case series. These data add “clinically relevant evidence” to a growing body of…
Otsuka Pharmaceutical has obtained exclusive rights to commercialize donidalorsen for hereditary angioedema (HAE) in the Asia-Pacific region. The deal is an extension of a previous license agreement that granted Otsuka the rights to commercialize the therapy in Europe. Ionis Pharmaceuticals, the therapy’s original developer, retains…
A research collaboration between Pentavere Research Group and Takeda Canada has led to the creation of one of the largest cohort datasets of patients with an ultra-rare form of hereditary angioedema (HAE) where C1 inhibitor (C1-INH) protein levels are normal. The public-private partnership seeks to “revolutionize” diagnosis and care…
KalVista Pharmaceuticals has submitted an application to the U.S. Food and Drug Administration (FDA) requesting the approval of sebetralstat, an oral on-demand treatment for people, 12 and older, with hereditary angioedema (HAE). The agency now has 60 days to determine whether the application, submitted in the form of…
Get regular updates to your inbox.